Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. reported its business and financial results for the fiscal year ended September 30, 2025. A key highlight was the December 2025 launch of LYMPHIR™ by its subsidiary, Citius Oncology, for the treatment of certain types of cutaneous T-cell lymphoma (CTCL). The company also reported advancements in its pipeline, including engaging with the FDA for Mino-Lok and exploring additional indications for LYMPHIR. Financially, Citius Pharma raised approximately $61 million in gross proceeds through capital raises by both Citius Pharma and Citius Oncology. For the fiscal year 2025, the company reported no revenues, R&D expenses of $9.2 million, and G&A expenses of $18.5 million. The net loss for the year was $39.7 million, or ($3.38) per share, compared to a net loss of $40.2 million, or ($5.97) per share, in fiscal year 2024. The company ended the fiscal year with $4.3 million in cash and cash equivalents.